Union Bancaire Privee UBP SA Invests $108,000 in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Union Bancaire Privee UBP SA bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 13,000 shares of the biotechnology company’s stock, valued at approximately $108,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AUPH. SG Americas Securities LLC boosted its stake in Aurinia Pharmaceuticals by 4,307.9% in the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after purchasing an additional 535,301 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Aurinia Pharmaceuticals in the 3rd quarter worth $3,330,000. AQR Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth about $1,155,000. Barclays PLC grew its stake in Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after purchasing an additional 143,072 shares during the last quarter. Finally, PDT Partners LLC increased its holdings in shares of Aurinia Pharmaceuticals by 76.0% in the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after purchasing an additional 130,204 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $8.14 on Thursday. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.17 billion, a PE ratio of -54.26 and a beta of 1.24. The business has a 50-day simple moving average of $8.71 and a 200-day simple moving average of $7.44.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the transaction, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.